Abstract
Pancreatic cancer is one of the highly aggressive malignant diseases worldwide. To achieve better treatment outcome of pancreatic cancer, in the current study we explore the underlying molecular mechanism of drug resistance in pancreatic cancer cells. We found that resistance to gemcitabine is associated with epithelial-mesenchymal transition (EMT) phenotype in a panel of pancreatic cancer cell lines. Notably, gemcitabine-resistant pancreatic cancer cells acquire EMT phenotype. Moreover, gemcitabine-resistant cells have increased migration and invasion activities. Furthermore, we observed the high expression of HIF-1α in gemcitabine-resistant cells. More importantly, inhibition of HIF-1α in gemcitabine-resistant cells caused partial reversal of EMT phenotype, suggesting that HIF-1α was critically involved in gemcitabine-resistant-mediated EMT. Therefore, targeting HIF-1α could be an effective strategy for the treatment of pancreatic cancer.
Keywords: Chemoresistance, EMT, gemcitabine, HIF-1α, pancreatic cancer.
Current Cancer Drug Targets
Title:Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells
Volume: 14 Issue: 4
Author(s): Rui Wang, Long Cheng, Jun Xia, Zishu Wang, Qiong Wu and Zhiwei Wang
Affiliation:
Keywords: Chemoresistance, EMT, gemcitabine, HIF-1α, pancreatic cancer.
Abstract: Pancreatic cancer is one of the highly aggressive malignant diseases worldwide. To achieve better treatment outcome of pancreatic cancer, in the current study we explore the underlying molecular mechanism of drug resistance in pancreatic cancer cells. We found that resistance to gemcitabine is associated with epithelial-mesenchymal transition (EMT) phenotype in a panel of pancreatic cancer cell lines. Notably, gemcitabine-resistant pancreatic cancer cells acquire EMT phenotype. Moreover, gemcitabine-resistant cells have increased migration and invasion activities. Furthermore, we observed the high expression of HIF-1α in gemcitabine-resistant cells. More importantly, inhibition of HIF-1α in gemcitabine-resistant cells caused partial reversal of EMT phenotype, suggesting that HIF-1α was critically involved in gemcitabine-resistant-mediated EMT. Therefore, targeting HIF-1α could be an effective strategy for the treatment of pancreatic cancer.
Export Options
About this article
Cite this article as:
Wang Rui, Cheng Long, Xia Jun, Wang Zishu, Wu Qiong and Wang Zhiwei, Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells, Current Cancer Drug Targets 2014; 14 (4) . https://dx.doi.org/10.2174/1568009614666140226114015
DOI https://dx.doi.org/10.2174/1568009614666140226114015 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry Multi-Kinase Inhibitors
Current Medicinal Chemistry The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy
Current Pharmaceutical Design Nucleoside Transport as a Potential Target for Chemotherapy in Malaria
Current Pharmaceutical Design Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews “Momordica balsamina: A Medicinal and Neutraceutical Plant for Health care Management”. Comments: Biotechnological Potential of M. balsamina Revealed
Current Pharmaceutical Biotechnology The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Multiple Myeloma Bone Marrow Niche
Current Pharmaceutical Biotechnology Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors
Current Medicinal Chemistry Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry